BACKGROUND: We previously reported improved neurodevelopmental outcomes at 2 years among infants treated with the erythropoiesis-stimulating agents (ESAs) darbepoetin alfa (darbepoetin) or erythropoietin. Here we characterize 4-year outcomes. METHODS: Former preterm infants randomly assigned to receive darbepoetin (10 μg/kg, once per week), erythropoietin (400 U/kg, 3 times/week), or placebo through 35 weeks' postconceptual age were evaluated at 3.5 to 4 years of age. For comparison, healthy children formerly delivered full term (term controls [TCs]) were also recruited. All participants were assessed by using measures of full-scale IQ (FSIQ) and general language from the Wechsler Preschool and Primary Scale of Intelligence, Third Edition, and an overall measure of executive function, on the basis of tests evaluating inhibitory control and spatial working memory. Rates of neurodevelopmental impairment were compared across groups. RESULTS: Multivariate analysis of variance compared children randomly assigned to ESAs (n = 39), placebo (n =14), and TCs (n = 24). FSIQ and performance IQ were significantly higher in the ESA group than in the placebo group (FSIQ: 91.1 ± 17.5 vs 79.2 ± 18.5, P = .036; performance IQ: 93.0 ± 17.0 vs 79.5 ± 19.5, P = .018). Follow-up analyses revealed that the children receiving ESAs performed better than those who received placebo on executive function tasks. The ESA group's performance was below that of TCs, but the results did not reach significance on executive function. The incidence of neurodevelopmental impairment was greater in the placebo group than in the ESA group. CONCLUSIONS:ESA-treated infants had better cognitive outcomes and less developmental impairment at 3.5 to 4 years of age compared with placebo-treated infants. ESAs show promise in improving long-term cognitive outcomes of infants born prematurely.
RCT Entities:
BACKGROUND: We previously reported improved neurodevelopmental outcomes at 2 years among infants treated with the erythropoiesis-stimulating agents (ESAs) darbepoetin alfa (darbepoetin) or erythropoietin. Here we characterize 4-year outcomes. METHODS: Former preterm infants randomly assigned to receive darbepoetin (10 μg/kg, once per week), erythropoietin (400 U/kg, 3 times/week), or placebo through 35 weeks' postconceptual age were evaluated at 3.5 to 4 years of age. For comparison, healthy children formerly delivered full term (term controls [TCs]) were also recruited. All participants were assessed by using measures of full-scale IQ (FSIQ) and general language from the Wechsler Preschool and Primary Scale of Intelligence, Third Edition, and an overall measure of executive function, on the basis of tests evaluating inhibitory control and spatial working memory. Rates of neurodevelopmental impairment were compared across groups. RESULTS: Multivariate analysis of variance compared children randomly assigned to ESAs (n = 39), placebo (n =14), and TCs (n = 24). FSIQ and performance IQ were significantly higher in the ESA group than in the placebo group (FSIQ: 91.1 ± 17.5 vs 79.2 ± 18.5, P = .036; performance IQ: 93.0 ± 17.0 vs 79.5 ± 19.5, P = .018). Follow-up analyses revealed that the children receiving ESAs performed better than those who received placebo on executive function tasks. The ESA group's performance was below that of TCs, but the results did not reach significance on executive function. The incidence of neurodevelopmental impairment was greater in the placebo group than in the ESA group. CONCLUSIONS: ESA-treated infants had better cognitive outcomes and less developmental impairment at 3.5 to 4 years of age compared with placebo-treated infants. ESAs show promise in improving long-term cognitive outcomes of infants born prematurely.
Authors: Masanori Iwai; R Anne Stetler; Juan Xing; Xiaoming Hu; Yanqin Gao; Wenting Zhang; Jun Chen; Guodong Cao Journal: Stroke Date: 2010-04-01 Impact factor: 7.914
Authors: Elizabeth E Rogers; Sonia L Bonifacio; Hannah C Glass; Sandra E Juul; Taeun Chang; Dennis E Mayock; David J Durand; Dongli Song; Anthony J Barkovich; Roberta A Ballard; Yvonne W Wu Journal: Pediatr Neurol Date: 2014-08-27 Impact factor: 3.372
Authors: Ruth L O'Gorman; Hans U Bucher; Ulrike Held; Brigitte M Koller; Petra S Hüppi; Cornelia F Hagmann Journal: Brain Date: 2014-12-22 Impact factor: 13.501
Authors: Lianne J Woodward; Caron A C Clark; Verena E Pritchard; Peter J Anderson; Terrie E Inder Journal: Dev Neuropsychol Date: 2011 Impact factor: 2.253
Authors: Stefano Vicari; Barbara Caravale; Giovanni Augusto Carlesimo; Anna Maria Casadei; Federico Allemand Journal: Neuropsychology Date: 2004-10 Impact factor: 3.295
Authors: John P Phillips; Erica Q Montague; Miranda Aragon; Jean R Lowe; Ronald M Schrader; Robin K Ohls; Arvind Caprihan Journal: Pediatr Neurol Date: 2011-10 Impact factor: 3.372
Authors: Robin K Ohls; Beena D Kamath-Rayne; Robert D Christensen; Susan E Wiedmeier; Adam Rosenberg; Janell Fuller; Conra Backstrom Lacy; Mahshid Roohi; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Hannah Peceny; Daniel C Cannon; Jean R Lowe Journal: Pediatrics Date: 2014-05-12 Impact factor: 7.124
Authors: Li Zhang; Michael Chopp; Rui Lan Zhang; Lei Wang; Jing Zhang; Ying Wang; Yier Toh; Manoranjan Santra; Mei Lu; Zheng Gang Zhang Journal: PLoS One Date: 2010-06-11 Impact factor: 3.240
Authors: Shenandoah Robinson; Christopher J Corbett; Jesse L Winer; Lindsay A S Chan; Jessie R Maxwell; Christopher V Anstine; Tracylyn R Yellowhair; Nicholas A Andrews; Yirong Yang; Laurel O Sillerud; Lauren L Jantzie Journal: Exp Neurol Date: 2017-12-26 Impact factor: 5.330
Authors: Charles Gasparovic; Arvind Caprihan; Ronald A Yeo; John Phillips; Jean R Lowe; Richard Campbell; Robin K Ohls Journal: Pediatr Radiol Date: 2018-01-15
Authors: Daniela Hoeber; Marco Sifringer; Yohan van de Looij; Josephine Herz; Stéphane V Sizonenko; Karina Kempe; Meray Serdar; Joanna Palasz; Martin Hadamitzky; Stefanie Endesfelder; Joachim Fandrey; Ursula Felderhoff-Müser; Ivo Bendix Journal: Oxid Med Cell Longev Date: 2016-07-14 Impact factor: 6.543
Authors: John Phillips; Ronald A Yeo; Arvind Caprihan; Daniel C Cannon; Shrena Patel; Sarah Winter; Michael Steffen; Richard Campbell; Susan Wiedmeier; Shawna Baker; Sean Gonzales; Jean Lowe; Robin K Ohls Journal: Pediatr Res Date: 2017-06-21 Impact factor: 3.756
Authors: Diana J Wallin; Tara G Zamora; Michelle Alexander; Kathleen M Ennis; Phu V Tran; Michael K Georgieff Journal: Pediatr Res Date: 2017-05-31 Impact factor: 3.756